In summary, sBCMA-Fc V3 with enhanced binding affinity to APRIL and BAFF resulted in better antitumor activity in both APRIL-driven MM and BAFF-driven DLBCL models. The gene discussed is TNFSF13B; the disease is Miyoshi myopathy.